Cardiology

The ROPA-DOP trial showed that low-dose dopamine had an insignificant impact on patient renal function, nor a significant trend toward greater diuresis.

Scott Solomon, MD, and Alvin Chandra, MD, discuss the findings of the PARADIGM-HF and QoL trial, and sacubitril's effect on HF patients quality of life.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The ongoing phase 3 trial has been selected for accelerated approval pathways in the US and Europe.

A 51-year-old man is seen in ED for progressive dyspnea, near syncope on exertion, bilateral edema. What does the tracing tell you?

A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

The valve is the first stented surgical aortic valve that is MRI-safe without restrictions and uses single, one-cut release to increase the ease of implantation.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

High-amylose maize starch with chemical add-ons prevented diabtes in susceptible mice in an Australian study.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

Her history includes diabetes, ESRD, coronary disease, and complete heart block after pacemaker implantation. What's your ECG read?

High HbA1c levels after the percutaneous cardiovascular intervention may help identify patients at long-term risk for adverse CV events.

With the global epidemic of obesity showing no signs of waning, physicians should be aware of the cardiac side effects of weight-loss drugs.

What topics are important for PCPs to understand to treat their CVD patients?

A tripartite strategy targets lifestyle change, treats CV risk factors and CV disease, and encourages more global thinking.

Breakthrough status for a new drug to treat familial hypercholesterolemia.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

Microbleeds in the brain appear to increase with cardiac procedures:Study.

The Absorb GT1 Bioresorbable Vascular Stent raised concerns at the FDA.

Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.